A New Era: Why the Time Has Come for Biopharma to Move to Continuous Bioprocessing

摘要

The pharmaceutical industry is approaching a watershed moment when it comes to drug manufacture. Rising cost pressures, market paradigm moves toward outcome-based medicine, fierce competition, and the ever-greater demand created by a growing and aging population are all putting unprecedented pressure on the sector. More complex therapeutics in greater numbers must be produced quicker and more cost effectively than ever before – and the industry is struggling to keep up.